argenx combines the diversity of the llama immune system with antibody engineering advancing a clinical pipeline to treat patients with cancer and severe autoimmune diseases. Our platforms allow us to unlock novel and complex targets and develop antibody-based drugs designed for greater efficacy and longer duration of effect. The strength of our team, our deep understanding of the disease biology and our committed collaborations with industry leaders contribute to the success of our journey.
argenx is listed on the Euronext Brussels exchange under the symbol ARGX.
argenx applies a unique suite of technologies to develop human antibody therapeutics against disease targets that are underserved in the biotherapeutics space. Combining our technology strengths with our antibody development capabilities and the complementary skills of our scientists enables us to create highly differentiated antibody programs for both our wholly-owned pipeline and in collaboration with our partners.
Our success is attributed to our complementary skills and antibody industry experience.
Board of directors
Our Board comprises life science industry veterans making key contributions to our success
We are always looking for people to join our talented team.